Allele-selective inhibition of trinucleotide repeat genes

Drug Discovery Today

Volumn 17, Issue 9-10, 2012, Pages 443-450

  Matsui, Masayuki ^a   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID;

GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRINUCLEOTIDE REPEAT;

ALLELES; ANIMALS; GENE SILENCING; HUMANS; NEURODEGENERATIVE DISEASES; NUCLEIC ACIDS; POLYMORPHISM, GENETIC; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84860665962     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.006     Document Type: Review

References (60)

1. P. Kozlowski Trinucleotide repeats in the human genome and exome Nucleic Acids Res. 38 2010 4027 4039
2. H.T. Orr, and H.Y. Zoghbi Trinucleotide repeat disorders Annu. Rev. Neurosci. 30 2007 575 621
3. R.J. Morse Pharmaceutical development for Huntington's disease D.C. Lo, R.E. Hughes, Neurobiology of Huntington's Disease: Applications to Drug Discovery 2nd edn 2011 CRC Press 197 224
4. F.O. Walker Huntington's disease Lancet 369 2007 218 228
5. S. Finkbeiner Huntington's disease Cold Spring Harb. Perspect. Biol. 3 2011 a007476
6. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
7. I. Sanchez Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 421 2003 373 379
8. D.E. Ehrnhoefer Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development Nat. Rev. Drug Discov. 10 2011 853 867
9. E.B. De Souza Novel therapeutic modalities to address nondrugable protein interaction targets Neuropsychopharmacology 34 2009 142 158
10. J. Scholefield, and M.J.A. Wood Therapeutic gene silencing strategies for polyglutamine disorders Trends Genet. 26 2009 29 38
11. S.Q. Harper RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc. Natl. Acad. Sci. U. S. A. 102 2005 5820 5825
12. R.L. Boudreau Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice Mol. Ther. 17 2009 1053 1063
13. V. Drouet Sustained effects of nonallele-specific Huntingtin silencing Ann. Neurol. 65 2009 276 285
14. M. DiFiglia Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits Proc. Natl. Acad. Sci. U. S. A. 104 2007 17204 17209
15. J.K. Watts, and D.R. Corey Silencing disease genes in the laboratory and the clinic J. Pathol. 226 2012 365 379
16. J. Nasir Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes Cell 81 1995 811 823
17. S. Zeitlin Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue Nat. Genet. 11 1995 155 163
18. J.K. White Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion Nat. Genet. 17 1997 404 410
19. M. Metzler Huntingtin is required for normal hematopoiesis Hum. Mol. Genet. 9 2000 387 394
20. J.M. Woda Inactivation of the Huntington's disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo BMC Dev. Biol. 5 2005 17 28
21. J.D. Godin Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis Neuron 67 2010 392 406
22. K. Huang Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14 Hum. Mol. Genet. 20 2011 3356 3365
23. V.M. Miller Allele-specific silencing of dominant disease genes Proc. Natl. Acad. Sci. U. S. A. 100 2003 7195 7200
24. Y. Ohnishi Enhancement of allele-discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi PLoS ONE 3 2008 e2248
25. Y. Li Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA Ann. Neurol. 56 2004 124 129
26. D.S. Schwarz Designing siRNA that distinguish between genes that differ by a single nucleotide PLoS Genet. 2 2006 e140
27. P.H.J. van Bilsen Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts Hum. Gene Ther. 19 2008 710 718
28. S. Alves Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado Joseph Disease PLoS ONE 3 2008 e3341
29. E.L. Pfister Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients Curr. Biol. 19 2009 774 778
30. M.S. Lombardi A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference Exp. Neurol. 217 2009 312 319
31. J. Scholefield Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype PLoS ONE 4 2009 e7232
32. Y. Zhang Allele-specific silencing of mutant Huntington's disease gene J. Neurochem. 108 2009 82 90
33. D.W.Y. Sah, and N. Aronin Oligonucleotide therapeutic approaches for Huntingtin Disease J. Clin. Invest. 121 2011 500 507
34. H. Huang Profiling of mismatch-discrimination in RNAi enabled rational design of allele-specific siRNAs Nucleic Acids Res. 37 2009 7560 7569
35. W.J. Krzyzosiak Triplet repeat RNA structure and is role as a pathogenic agent and therapeutic target Nucleic Acids Res. 2011 10.1093/nar/gkr729
36. G. Michlewski, and W.J. Krzyzosiak Molecular architecture of CAG repeats in human disease related transcripts J. Mol. Biol. 340 2004 665 679
37. M. de Mezer Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference Nucleic Acids Res. 39 2011 3852 3863
38. F. Muntoni, and M.J. Wood Targeting RNA to treat neuromuscular disease Nat. Rev. Drug Discov. 10 2011 621 637
39. N.M. Kuyumcu-Martinez Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation Mol. Cell 28 2007 68 78
40. S.A.M. Mulders Triplet-repeat oligonucletide-mediated reversal of RNA toxicity in myotonic dystrophy Proc. Natl. Acad. Sci. U. S. A. 106 2009 13915 13920
41. T.M. Wheeler Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA Science 325 2009 336 339
42. J. Hu Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs Nat. Biotechnol. 27 2009 478 484
43. D.A. Braasch, and D.R. Corey Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA Chem. Biol. 8 2001 1 7
44. K.T. Gagnon Allele-selective silencing of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat Biochemistry 49 2010 10166 10178
45. Y. Wang Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex Nature 456 2008 921 926
46. J. Hu Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism Chem. Biol. 17 2010 1183 1188
47. A. Fiszer Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats Nucleic Acids Res. 39 2011 5578 5585
48. J. Hu Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs Biol. Chem. 392 2011 315 325
49. J. Hu Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA Ann. N.Y. Acad. Sci. 1175 2009 24 31
50. N.M. Goemans Systemic administration of PRO051 in Duchenne's muscular dystrophy N. Engl. J. Med. 364 2011 1513 1522
51. S. Cirak Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, does escalation study Lancet 378 2011 595 605
52. R.A. Smith Antisense oligonucleotide therapy for neurodegenerative disease J. Clin. Invest. 116 2006 2290 2296
53. W. Querbes Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes Oligonucleotides 19 2008 23 29
54. M.A. Passini Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy Sci. Transl. Med. 3 2011 72ra18
55. K.T. Gagnon HD therapeutics - CHDI fifth annual conference IDrugs 13 2010 219 223
56. J. Lichota Macromolecular drug transport into the brain using targeted therapy J. Neurochem. 113 2010 1 13
57. J.L. McBride Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi Proc. Natl. Acad. Sci. U. S. A. 105 2008 5868 5873
58. C.A. Stein, and S. Goel Therapeutic oligonucleotides - the road not taken Clin. Cancer Res. 2011 10.1158/1078-0432.CCR-11-2013
59. F. Adkim Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidemia Eur. Heart J. 2011 10.1093/eurheartj/
60. K.T. Gagnon Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide-oligospermine conjugates J. Am. Chem. Soc. 133 2011 8404 8407